# Bakkt, Inc.: financial statements, quarterly

BKKT · NYSE · CIK 1820302 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bkkt.md) · [Financials](/companies/bkkt/financials.md) · [Filings](/companies/bkkt/filings.md) · [Insiders](/companies/bkkt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bkkt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [205](/filings/0001628280-24-047906.md) | [161 d](/filings/0001628280-26-019870.md) | [855](/filings/0001628280-25-024743.md) | [510](/filings/0001628280-25-039625.md) | [328](/filings/0001628280-24-047906.md) | [1,748 d](/filings/0001628280-26-019870.md) | [1,075](/filings/0001628280-25-024743.md) | [578](/filings/0001628280-25-039625.md) | not reported | not reported | not reported | not reported |
| Operating income | $m | [(52.9)](/filings/0001628280-24-047906.md) | [(6.8) d](/filings/0001628280-26-019870.md) | [(31.8)](/filings/0001628280-25-024743.md) | [(22.0)](/filings/0001628280-25-039625.md) | [(25.1)](/filings/0001628280-25-051180.md) | [(10.0) d](/filings/0001628280-26-019870.md) | [(15.4)](/filings/0001628280-26-033576.md) | [(16.1)](/filings/0001628280-26-055275.md) | [(25.3)](/filings/0001628280-25-051180.md) | [(91.0) d](/filings/0001628280-26-019870.md) | [(16.9)](/filings/0001628280-26-033576.md) | [(19.6)](/filings/0001628280-26-055275.md) |
| Income tax | $m | [0.2](/filings/0001628280-24-047906.md) | [(0.0) d](/filings/0001628280-26-019870.md) | [0.2](/filings/0001628280-25-024743.md) | [0.1](/filings/0001628280-25-039625.md) | [(0.1)](/filings/0001628280-25-051180.md) | [(0.0) d](/filings/0001628280-26-019870.md) | [0.0](/filings/0001628280-26-033576.md) | [0.1](/filings/0001628280-26-055275.md) | [(0.0)](/filings/0001628280-25-051180.md) | [(0.2) d](/filings/0001628280-26-019870.md) | [0.0](/filings/0001628280-26-033576.md) | [0.0](/filings/0001628280-26-055275.md) |
| Net income | $m | [(17.3)](/filings/0001628280-24-047906.md) | [(26.7) d](/filings/0001628280-26-019870.md) | [(8.2)](/filings/0001628280-25-024743.md) | [(16.4)](/filings/0001628280-25-039625.md) | [(2.9)](/filings/0001628280-25-051180.md) | [(19.2) d](/filings/0001628280-26-019870.md) | [7.7](/filings/0001628280-26-033576.md) | [(14.7)](/filings/0001628280-26-055275.md) | [(14.9)](/filings/0001628280-25-051180.md) | [(85.3) d](/filings/0001628280-26-019870.md) | [(11.7)](/filings/0001628280-26-033576.md) | [80.8](/filings/0001628280-26-055275.md) |
| Diluted EPS | $ per share | [(4.74)](/filings/0001628280-24-047906.md) | not reported | [(1.86)](/filings/0001628280-25-024743.md) | [(2.67)](/filings/0001628280-25-039625.md) | [(0.45)](/filings/0001628280-25-051180.md) | not reported | [1.13](/filings/0001628280-26-033576.md) | [(2.16)](/filings/0001628280-26-055275.md) | [(1.15)](/filings/0001628280-25-051180.md) | not reported | [(0.41)](/filings/0001628280-26-033576.md) | [1.94](/filings/0001628280-26-055275.md) |
| Basic EPS | $ per share | [(4.74)](/filings/0001628280-24-047906.md) | not reported | [(1.86)](/filings/0001628280-25-024743.md) | [(2.67)](/filings/0001628280-25-039625.md) | [(0.45)](/filings/0001628280-25-051180.md) | not reported | [1.18](/filings/0001628280-26-033576.md) | [(2.16)](/filings/0001628280-26-055275.md) | [(1.15)](/filings/0001628280-25-051180.md) | not reported | [(0.41)](/filings/0001628280-26-033576.md) | [1.96](/filings/0001628280-26-055275.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [68.2](/filings/0001628280-24-047906.md) | [52.9](/filings/0001628280-26-019870.md) | [56.6](/filings/0001628280-25-024743.md) | [47.5](/filings/0001628280-25-039625.md) | [29.0](/filings/0001628280-25-051180.md) | [39.0](/filings/0001628280-26-019870.md) | [23.0](/filings/0001628280-26-033576.md) | [43.5](/filings/0001628280-26-055275.md) | [58.3](/filings/0001628280-25-051180.md) | [27.0](/filings/0001628280-26-055275.md) | [80.0](/filings/0001628280-26-033576.md) | [50.0](/filings/0001628280-26-055275.md) |
| Current assets | $m | [694](/filings/0001820302-24-000025.md) | [181](/filings/0001628280-25-013959.md) | [1,490](/filings/0001820302-24-000094.md) | [1,157](/filings/0001820302-24-000119.md) | [1,098](/filings/0001628280-24-047906.md) | [184](/filings/0001628280-26-019870.md) | [92.5](/filings/0001628280-25-024743.md) | [110](/filings/0001628280-25-039625.md) | [120](/filings/0001628280-25-051180.md) | [72.2](/filings/0001628280-26-055275.md) | [125](/filings/0001628280-26-033576.md) | [97.4](/filings/0001628280-26-055275.md) |
| Total assets | $m | [847](/filings/0001820302-24-000025.md) | [265](/filings/0001628280-25-013959.md) | [1,576](/filings/0001820302-24-000094.md) | [1,243](/filings/0001820302-24-000119.md) | [1,183](/filings/0001628280-24-047906.md) | [269](/filings/0001628280-26-019870.md) | [176](/filings/0001628280-25-024743.md) | [190](/filings/0001628280-25-039625.md) | [258](/filings/0001628280-25-051180.md) | [163](/filings/0001628280-26-055275.md) | [213](/filings/0001628280-26-033576.md) | [404](/filings/0001628280-26-055275.md) |
| Current liabilities | $m | [594](/filings/0001820302-24-000025.md) | [101](/filings/0001628280-25-013959.md) | [1,398](/filings/0001820302-24-000094.md) | [1,077](/filings/0001820302-24-000119.md) | [1,042](/filings/0001628280-24-047906.md) | [138](/filings/0001628280-26-019870.md) | [58.4](/filings/0001628280-25-024743.md) | [93.2](/filings/0001628280-25-039625.md) | [53.8](/filings/0001628280-25-051180.md) | [33.0](/filings/0001628280-26-055275.md) | [30.3](/filings/0001628280-26-033576.md) | [31.0](/filings/0001628280-26-055275.md) |
| Total liabilities | $m | [636](/filings/0001820302-24-000025.md) | [130](/filings/0001628280-25-013959.md) | [1,445](/filings/0001820302-24-000094.md) | [1,140](/filings/0001820302-24-000119.md) | [1,081](/filings/0001628280-24-047906.md) | [207](/filings/0001628280-26-019870.md) | [94.8](/filings/0001628280-25-024743.md) | [132](/filings/0001628280-25-039625.md) | [130](/filings/0001628280-25-051180.md) | [50.0](/filings/0001628280-26-055275.md) | [42.5](/filings/0001628280-26-033576.md) | [49.2](/filings/0001628280-26-055275.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [69.3](/filings/0001820302-24-000025.md) | [48.3](/filings/0001628280-25-013959.md) | [57.0](/filings/0001820302-24-000094.md) | [47.8](/filings/0001820302-24-000119.md) | [50.5](/filings/0001628280-24-047906.md) | [33.9](/filings/0001628280-26-019870.md) | [44.1](/filings/0001628280-25-024743.md) | [35.3](/filings/0001628280-25-039625.md) | [114](/filings/0001628280-25-051180.md) | [113](/filings/0001628280-26-055275.md) | [171](/filings/0001628280-26-033576.md) | [354](/filings/0001628280-26-055275.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [24.6 d](/filings/0001628280-24-047906.md) | [(6.8) d](/filings/0001628280-26-019870.md) | [38.4](/filings/0001628280-25-024743.md) | [(65.9) d](/filings/0001628280-25-039625.md) | [(25.1) d](/filings/0001628280-25-051180.md) | [31.4 d](/filings/0001628280-26-019870.md) | [(101)](/filings/0001628280-26-033576.md) | [5.4 d](/filings/0001628280-26-055275.md) | [(46.7) d](/filings/0001628280-25-051180.md) | [(10.8) d](/filings/0001628280-26-019870.md) | [(12.1)](/filings/0001628280-26-033576.md) | [(14.8) d](/filings/0001628280-26-055275.md) |
| Capital expenditure | $m | [1.9 d](/filings/0001628280-24-047906.md) | [1.5 d](/filings/0001628280-25-013959.md) | [1.8](/filings/0001628280-25-024743.md) | [0.5 d](/filings/0001628280-25-039625.md) | [0.5 d](/filings/0001628280-24-047906.md) | [0.3 d](/filings/0001628280-25-013959.md) | [0.1](/filings/0001628280-25-024743.md) | [0.0 d](/filings/0001628280-25-039625.md) | not reported | not reported | not reported | not reported |
| Share repurchases | $m | [0.0 d](/filings/0001628280-24-047906.md) | [0.1 d](/filings/0001628280-25-013959.md) | [2.3](/filings/0001628280-25-024743.md) | [0.1 d](/filings/0001628280-25-039625.md) | [0.1 d](/filings/0001628280-25-051180.md) | [0.3 d](/filings/0001628280-25-013959.md) | [0.9](/filings/0001628280-26-033576.md) | [0.8 d](/filings/0001628280-26-055275.md) | [1.7 d](/filings/0001628280-25-051180.md) | not reported | [0.3](/filings/0001628280-26-033576.md) | [0.0 d](/filings/0001628280-26-055275.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [76.6](/filings/0001820302-24-000025.md) | [3.3](/filings/0001820302-24-000094.md) | [3.6](/filings/0001820302-24-000119.md) | [3.7](/filings/0001628280-24-047906.md) | [4.4](/filings/0001628280-25-024743.md) | [6.2](/filings/0001628280-25-039625.md) | [6.4](/filings/0001628280-25-051180.md) | [7.2](/filings/0001628280-26-033576.md) | [6.8](/filings/0001628280-26-055275.md) | [13.0](/filings/0001628280-25-051180.md) | [28.4](/filings/0001628280-26-033576.md) | [41.7](/filings/0001628280-26-055275.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 45,069,458 at 2026-08-05, from the cover of the [10-Q filed 2026-08-10](/filings/0001628280-26-055275.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.